Nonetheless, K-562 (CML) and Jurkat (T-ALL) lines subjected to RNF5 KD do not exhibit growth inhibition or undergo cell death, while similarly treated AML lines do. The gene discussed is RNF5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.